heptyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate | 1187550-15-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: heptyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 1187550-15-7
• 化学式: C₁₅H₂₉NO₄
• 分子量: 287.4
• InChiKey: FDUSCCONAIQPET-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  heptyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 生成 (S)-2-aminopropanoic acid heptyl ester hydrochloride
  参考文献：
  名称：

  Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

  摘要：

  The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2'-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.04.043
• 作为产物：
  描述：

  N-叔丁氧羰基-L-丙氨酸 、 正庚醇 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 heptyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
  参考文献：
  名称：

  Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

  摘要：

  The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2'-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.04.043